All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome

December 10th 2023

The high-precision cell therapy Orca-T demonstrated high rates of relapse-free survival, overall survival, and graft-vs-host disease RFS at 1 year, as well as a low incidence of GVHD in patients with intermediate- to high-risk myelodysplastic syndrome.

Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies

December 10th 2023

The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy in younger and older patients with hematologic malignancies, according to data from a phase 1b study.

Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL

December 10th 2023

The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.

Venetoclax Is Associated With Durable ORRs in Real-World Population of BTK Inhibitor–Exposed CLL/SLL

December 10th 2023

Venetoclax-based therapy generated durable responses both overall and in the second or third line following covalent BTK inhibitor discontinuation in real-world patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Ultrasensitive BCMA CARs Deliver Responses With Tolerable Safety in R/R Multiple Myeloma

December 10th 2023

The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy is safe and feasible in patients with relapsed/refractory multiple myeloma.

Golidocitinib Demonstrates Efficacy in Relapsed/Refractory PTCL

December 10th 2023

Golidocitinib displayed antitumor activity and an acceptable safety profile in patients with refractory/relapsed peripheral T-cell lymphoma, according to data from the pivotal phase 2 JACKPOT8 study.

Pirtobrutinib Demonstrates Durable Efficacy in Covalent BTK Inhibitor–Pretreated CLL/SLL

December 10th 2023

Pirtobrutinib continued to showcase clinically meaningful efficacy in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a covalent BTK inhibitor.

Safety of Outpatient CAR T-Cell Therapy May Be Improved With Integrated Management Process

December 10th 2023

The utilization of remote patient monitoring within the first 30 days of outpatient CAR T-cell therapy can promote patient safety, reduce costs, and decrease hospitalization rates by allowing patients with hematologic malignancies to connect with a virtual care platform.

Zanubrutinib Showcases Sustained PFS Benefit Vs Ibrutinib in R/R CLL/SLL

December 10th 2023

Zanubrutinib continued to demonstrate improved progression-free survival benefit over ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, according to extended follow-up data from the phase 3 ALPINE trial.

Dana-Farber Launches New Centers to Detect and Intercept Cancer

December 10th 2023

Dana-Farber Cancer Institute is launching a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and to prevent cancer from arising in individuals at increased risk for the disease.

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

December 9th 2023

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL

December 9th 2023

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.

Brexu-Cel Induces Responses in Real-World Population of High-Risk R/R MCL

December 9th 2023

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML

December 9th 2023

Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.

Real-World Analysis Sheds Light on Safety and Efficacy of Teclistamab in R/R Multiple Myeloma

December 9th 2023

The T-cell redirecting bispecific antibody teclistamab-cqyv demonstrated efficacy and a tolerable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma consistent with that of those enrolled in the phase 2 MajesTEC-1 trial.

AI Algorithm Effectively Differentiates Between pre-PMF/ET

December 9th 2023

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

All-Oral Arsenic Trioxide, All-Trans Retinoic Acid/Ascorbic Acid Proves Effective, Safe in Acute Promyelocytic Leukemia

December 9th 2023

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer

December 9th 2023

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC

December 8th 2023

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

EFS Benefit With Neoadjuvant Pembrolizumab/Chemo Combo, Adjuvant Pembrolizumab Upheld in High-Risk Early TNBC

December 8th 2023

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.